ANTILIPEMIC AGENT;
BONE MORPHOGENETIC PROTEIN 2;
COMPACTIN;
ESTROGEN RECEPTOR;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE;
LUCIFERASE;
MEVINOLIN;
SIMVASTATIN;
BONE DENSITY;
CHOLESTEROL BLOOD LEVEL;
COMPETITIVE INHIBITION;
DRUG MECHANISM;
HUMAN;
HUMAN CELL;
HUMAN TISSUE;
HYPERCHOLESTEROLEMIA;
OSTEOPOROSIS;
PRIORITY JOURNAL;
PROMOTER REGION;
SHORT SURVEY;
ANIMALS;
ANTICHOLESTEREMIC AGENTS;
BONE DISEASES, METABOLIC;
BONE MORPHOGENETIC PROTEINS;
BONE RESORPTION;
FEMALE;
HUMANS;
HYPERCHOLESTEROLEMIA;
MALE;
MODELS, BIOLOGICAL;
OSTEOPOROSIS;
TRANSFORMING GROWTH FACTOR BETA;
Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme a reductase and a cholesterol-towering agent
Alberts, A.W. et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-towering agent. Proc. Natl. Acad. Sci. USA 77, 3957-3961 (1980).
Hydrophilicity/lipophilicity: Relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors
Hamelin, B.A. & Turgeon, J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol. Sci. 19, 26-37 (1998).
N2-containing bisphosphonates risedronate and ibandronate stimulate bone formation in organ culture
abstract
Garrett, I.R., Escobedo, A. & Mundy, G.R. N2-containing bisphosphonates risedronate and ibandronate stimulate bone formation in organ culture, J. Bone Miner. Res. 14, S525 (abstract) (1999).
J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras
Luckman, S.P. et al. J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. 13, 58-589 (1998).
Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro
Fisher, J.E. et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro. Proc. Natl. Acad. Sci. USA 96, 133-138 (1999).
Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates
van Beek, E. et al. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem. Biophys. Res. Commun, 264, 108-111 (1999).
